For instance, tocilizumab, targeting the IL-6R, is approved for rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease, while sarilumab, also targeting the IL-6R, is in late-stage clinical trials [8]. Here, IL6R is linked to juvenile idiopathic arthritis.